http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101742023-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1fc6b9400d35e1b47e552c1e2ee7797e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4b7365de74045e8a7e0407f304451e1b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S514-877 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate | 2016-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7592c1c01f67c171eb6698c8fb28014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb281681993624ba8ee8495f93c58229 |
| publicationDate | 2017-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101742023-B1 |
| titleOfInvention | Pharmacedual composition comprising bortezomib for preventing or treating gallstone |
| abstract | The present invention relates to a prophylactic or pharmaceutical composition containing bortezomib as an active ingredient, wherein the bortezomib inhibits the production of cholesterol-induced gallstones when administered to a rats fed with a high cholesterol diet, Inhibited the expression of ABCG5 and ABCG8 associated with cholesterol secretion, inhibited the expression of m-SREBP2 and MHGR associated with cholesterol synthesis, and inhibited mSREBP2 and HMGR protein expression. In addition, we confirmed that bortezomib does not affect caspase-3 cleavage while inhibiting Cyp7a1 protein expression in a hepatocyte-dependent manner, suggesting inhibition of gallstone formation through inhibition of bile acid and cholesterol production, Can be usefully used for the prevention and treatment of gallstone disease. |
| priorityDate | 2016-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 90.